PA
Parnax Lab Ltd (PARNAXLAB)
₹114.87
Mkt cap
₹134 Cr
P/E ratio
15.60
P/B
1.35
Div yield
0.00%
ROE
14.20%
ROCE
13.80%
EPS (TTM)
₹7.36
Book value
₹85
52W range
73–150
Sector
Healthcare
Price history
Previous close
Incorporated in 1985, Parnax Lab Ltd manufactures and exports Pharmaceutical Formulations [1]
NSE PARNAXLABBSE 506128
Health check
Constructive
ValuationCheap
ProfitabilityAverage
GrowthModerate
TechnicalsNeutral
52-week range
−23.16% from high₹115
₹73+58.44% from low₹150
Current
₹114.87
Prev close
₹113.41
Day
+1.29%
Price performance
1D
+2.28%
1W
+7.41%
1M
+11.48%
3M
−4.99%
6M
—
1Y
—
YTD
−3.99%
Financials
Revenue, profit & margin
P/E ratio
15.6×
PARNAXLAB is 52% below the sector median of 32.8×
PARNAXLAB15.6×
Sector median32.8×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 42.61 | 50.99 | 46.37 | 50.12 | 48.36 | 40.22 | 49.04 | 53.38 | 62.60 | 62.94 | 69.63 | 56.80 | 69.26 | |
| YoY Sales growth | -1.23% | +8.91% | +13.35% | +2.83% | +13.49% | -21.12% | +5.76% | +6.50% | +29.45% | +56.49% | +41.99% | +6.41% | +10.64% | |
| Expenses | 37.32 | 45.02 | 40.58 | 41.50 | 41.12 | 35.95 | 42.41 | 45.94 | 54.52 | 56.09 | 64.75 | 52.49 | 62.36 | |
| Operating Profit | 5.29 | 5.97 | 5.79 | 8.62 | 7.24 | 4.27 | 6.63 | 7.44 | 8.08 | 6.85 | 4.88 | 4.31 | 6.90 | |
| OPM % | 12.41% | 11.71% | 12.49% | 17.20% | 14.97% | 10.62% | 13.52% | 13.94% | 12.91% | 10.88% | 7.01% | 7.59% | 9.96% | |
| Other Income | 0.22 | 0.10 | 0.25 | 0.11 | 0.95 | 0.19 | 0.43 | 0.18 | 0.63 | -0.17 | 1.76 | 0.15 | 0.21 | |
| Interest | 1.43 | 1.35 | 1.41 | 1.50 | 1.38 | 1.23 | 1.28 | 1.22 | 1.40 | 1.47 | 1.61 | 1.64 | 1.60 | |
| Depreciation | 1.74 | 1.78 | 1.84 | 1.83 | 1.94 | 1.79 | 1.83 | 1.94 | 2.10 | 1.96 | 2.04 | 2.22 | 2.33 | |
| Profit before tax | 2.34 | 2.94 | 2.79 | 5.40 | 4.87 | 1.44 | 3.95 | 4.46 | 5.21 | 3.25 | 2.99 | 0.60 | 3.18 | |
| Tax % | 20.09% | 25.85% | 19.35% | 26.30% | 29.77% | 16.67% | 26.08% | 26.46% | 30.33% | 16.62% | 27.09% | 28.33% | 31.13% | |
| Net Profit | 1.87 | 2.18 | 2.24 | 3.99 | 3.42 | 1.21 | 2.93 | 3.28 | 3.62 | 2.71 | 2.19 | 0.43 | 2.18 | |
| EPS in Rs | 1.63 | 1.90 | 1.95 | 3.47 | 2.97 | 1.05 | 2.54 | 2.85 | 3.16 | 2.36 | 1.90 | 0.37 | 1.90 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202672.30%Promoter
Promoters72.30%
Public27.70%0.01
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,871.50 | 36.49 | 4,49,036 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,049.00 | 85.83 | 2,93,316 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,610.70 | 80.78 | 1,75,376 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,322.50 | 93.66 | 1,25,488 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,202.00 | 26.46 | 1,19,900 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,398.20 | 41.71 | 1,16,788 | 0.57% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,417.00 | 36.86 | 1,14,478 | 0.92% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Parnax Lab | ₹116.42 | 15.59 | 134 | 0.00% | 2 | −39.94% | 69 | +10.64% | 13.75% |
| Median: 160 Co. | ₹439.32 | 32.75 | 2,001 | 0.08% | 13 | +33.73% | 179 | +21.23% | 14.94% |
Filings
Annual reports15
Credit ratings6
Announcements5
Results For The Quarter And Half Year Ended September 30, 2026 12 NovBoard Meeting Outcome for Outcome Of BM Dated 12.11.2026 12 Nov - Board approved standalone and consolidated Q2/H1 FY2026 results on 12 November 2026.Board Meeting Intimation for Consideration And Approval Of Financial Results Along With Limited Review Report For The Quarter (Q2) And Half Year Ended 30Th September, 2026. 3 Nov - Board meeting on November 12, 2026 to approve Q2 and half-year unaudited financial results.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 14 Oct - Regulation 74(5) certificate: no dematerialization requests received for quarter ended September 30, 2026.Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 30 Sep






